One of the suggested mechanisms in which PPARγ contributes in hepatic steatosis is by enhancing the de novo lipogenesis through stimulating LXR, which in turn activates SREBP-1c, ChREBP, FAS, and ACC [53]. Here, MLXIPL is linked to fatty liver disease.